l-mind study: r/r dlbcl
Published 4 years ago • 117 plays • Length 6:05Download video MP4
Download video MP3
Similar videos
-
1:32
dr. kahl on findings from the l-mind study with tafasitamab in dlbcl
-
2:52
anti-cd19 monoclonal antibody therapy in dlbcl
-
6:37
l-mind trial in relapsed/refractory dlbcl
-
5:51
re-mind versus l-mind regimen
-
1:24
assist. prof. kami maddocks: l-mind study in r/r dlbcl - tolerability
-
4:46
treatment of r/r dlbcl: cd19-targeted monoclonal antibodies
-
2:16
study go29365 in relapsed-refractory dlbcl
-
4:05
selecting therapy for relapsed-refractory dlbcl
-
2:57
future directions for r/r dlbcl
-
1:14
tafasitamab plus lenalidomide approval generates excitement for second-line dlbcl
-
2:28
prof. gilles salles: l-mind study: mor208 lenalidomide in r/r dlbcl - icml 2017
-
3:16
cd19-targeted mabs in relapsed/refractory dlbcl
-
1:36
the use of tafasitamab and lenalidomide in r/r dlbcl
-
3:15
treatment limitations in dlbcl
-
1:19:12
the next phase of targeted therapy in mcl and dlbcl
-
46:48
relapsed and refractory diffuse large b-cell lymphoma
-
58:24
update on diffuse large b-cell lymphoma | lrf webinars
-
21:56
what's new in the approach to dlbcl upfront and in the relapsed setting beyond car t
-
1:22
dr. burke on the ongoing first-mind trial with tafasitamab in dlbcl